{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:37:33Z","timestamp":1789029453964,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1124\/mol.104.000299","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T00:40:49Z","timestamp":1086655249000},"page":"538-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release"],"prefix":"10.1016","volume":"66","author":[{"given":"Lifen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.104.000299_bib1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-3565(24)36503-6","article-title":"Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function","volume":"280","author":"Albuquerque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.104.000299_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1152\/jn.1995.73.3.1234","article-title":"Temporal and spatial characteristics of tonically active neurons of the primate\u2019s striatum","volume":"73","author":"Aosaki","year":"1995","journal-title":"J Neurophysiol"},{"key":"10.1124\/mol.104.000299_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00019052-200208000-00007","article-title":"Neuropsychiatric symptoms in the dementias","volume":"15","author":"Assal","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/mol.104.000299_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0306-4522(00)00180-9","article-title":"Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors","volume":"99","author":"Barnes","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/mol.104.000299_bib5","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1523\/JNEUROSCI.19-13-05586.1999","article-title":"Spontaneous activity of neostriatal cholinergic interneurons in vitro","volume":"19","author":"Bennett","year":"1999","journal-title":"J Neurosci"},{"key":"10.1124\/mol.104.000299_bib6","series-title":"Classical Transmitters in the CNS, Part I","first-page":"55","article-title":"Dopamine-containing systems in the CNS","author":"Bj\u00f6rklund","year":"1984"},{"issue":"Suppl 1","key":"10.1124\/mol.104.000299_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000051229","article-title":"Galantamine: therapeutic effects beyond cognition","volume":"11","author":"Blesa","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1124\/mol.104.000299_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0022-3565(25)12928-5","article-title":"Pharmacological evaluation of novel Alzheimer\u2019s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine","volume":"277","author":"Bores","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.104.000299_bib9","series-title":"Classical Transmitters and Transmitter Receptors in the CNS","first-page":"1","article-title":"Histochemical distribution of acetylcholinesterase in the central nervous system: clues to the localization of cholinergic neurons","author":"Butcher","year":"1984"},{"key":"10.1124\/mol.104.000299_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0166-2236(99)01501-5","article-title":"Acetylcholine-mediated modulation of striatal function","volume":"23","author":"Calabresi","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1124\/mol.104.000299_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0306-4522(00)00071-3","article-title":"Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson\u2019s disease and Alzheimer\u2019s disease and in relation to neuroleptic medication","volume":"98","author":"Court","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/mol.104.000299_bib12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer\u2019s disease: a disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science (Wash DC)"},{"key":"10.1124\/mol.104.000299_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1124\/mol.64.5.1217","article-title":"The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release","volume":"64","author":"Dajas-Bailador","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.104.000299_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0006-3223(00)01011-8","article-title":"Overview of nicotinic receptors and their roles in the central nervous system","volume":"49","author":"Dani","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1124\/mol.104.000299_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-510X(02)00267-8","article-title":"Treatment options: the latest evidence with galantamine (Reminyl)","volume":"203\u2013204","author":"Erkinjuntti","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1124\/mol.104.000299_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.1124\/mol.104.000299_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0166-2236(91)90117-D","article-title":"Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence","volume":"14","author":"Fibiger","year":"1991","journal-title":"Trends Neurosci"},{"key":"10.1124\/mol.104.000299_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1124\/mol.104.000299_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1471-4159.2001.00019.x","article-title":"Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum","volume":"76","author":"Grady","year":"2001","journal-title":"J Neurochem"},{"key":"10.1124\/mol.104.000299_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1523\/JNEUROSCI.13-04-01551.1993","article-title":"Immunocytochemical localization of a neuronal nicotinic receptor: the \u03b22-subunit","volume":"13","author":"Hill","year":"1993","journal-title":"J Neurosci"},{"key":"10.1124\/mol.104.000299_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0026-895X(25)09170-9","article-title":"Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities","volume":"41","author":"Hodge","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.104.000299_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0361-9230(99)00226-9","article-title":"Individual variability of dopamine release from nucleus accumbens induced by nicotine","volume":"51","author":"Johnson","year":"2000","journal-title":"Brain Res Bull"},{"key":"10.1124\/mol.104.000299_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cne.1345","article-title":"Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones","volume":"439","author":"Jones","year":"2001","journal-title":"J Comp Neurol"},{"key":"10.1124\/mol.104.000299_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0893-133X(98)00044-X","article-title":"Loss of dopamine D2 receptors in Alzheimer\u2019s disease with parkinsonism but not Parkinson\u2019s or Alzheimer\u2019s disease","volume":"19","author":"Joyce","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/mol.104.000299_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine\u2014a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1124\/mol.104.000299_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/gps.448","article-title":"Neuropsychiatric disturbance in Alzheimer\u2019s disease clusters into three groups: the Cache County study","volume":"16","author":"Lyketsos","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1124\/mol.104.000299_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-3223(00)01109-4","article-title":"Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer\u2019s disease","volume":"49","author":"Maelicke","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1124\/mol.104.000299_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-4328(00)00214-X","article-title":"Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer\u2019s disease","volume":"113","author":"Maelicke","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1124\/mol.104.000299_bib29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/dmd.30.5.553","article-title":"The metabolism and excretion of galantamine in rats, dogs and humans","volume":"30","author":"Mannens","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/mol.104.000299_bib30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1046\/j.1471-4159.1997.68041511.x","article-title":"Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats","volume":"68","author":"Marshall","year":"1997","journal-title":"J Neurochem"},{"key":"10.1124\/mol.104.000299_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0959-4388(96)80118-8","article-title":"Presynaptic ionotropic receptors","volume":"6","author":"McGehee","year":"1996","journal-title":"Curr Opin Neurobiol"},{"key":"10.1124\/mol.104.000299_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0006-8993(02)03542-4","article-title":"Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients","volume":"960","author":"Mulugeta","year":"2003","journal-title":"Brain Res"},{"issue":"Suppl 4","key":"10.1124\/mol.104.000299_bib33","first-page":"S53","article-title":"PET studies and cholinergic therapy in Alzheimer\u2019s disease","volume":"155","author":"Nordberg","year":"1999","journal-title":"Rev Neurol (Paris)"},{"key":"10.1124\/mol.104.000299_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1358\/mf.2000.22.8.701373","article-title":"Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro","volume":"22","author":"Ogura","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1124\/mol.104.000299_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0165-6147(02)02056-4","article-title":"Pharmacotherapy for Alzheimer\u2019s disease: progress and prospects","volume":"23","author":"Palmer","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/mol.104.000299_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0301-0082(99)00045-3","article-title":"Neuronal nicotinic receptors in the human brain","volume":"61","author":"Paterson","year":"2000","journal-title":"Prog Neurobiol"},{"key":"10.1124\/mol.104.000299_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","article-title":"Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases","volume":"393","author":"Perry","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.104.000299_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.bmb.a072100","article-title":"The cholinergic hypothesis\u2014ten years on","volume":"42","author":"Perry","year":"1986","journal-title":"Br Med Bull"},{"key":"10.1124\/mol.104.000299_bib39","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0896-6273(00)80134-8","article-title":"Nicotinic receptors in the development and modulation of CNS synapses","volume":"16","author":"Role","year":"1996","journal-title":"Neuron"},{"key":"10.1124\/mol.104.000299_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-0404.2000.00310.x","article-title":"Galantamine is an allosterically potentiating ligand of the human alpha4\/beta2 nAChR","volume":"176","author":"Samochocki","year":"2000","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1124\/mol.104.000299_bib41","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12219-5","article-title":"The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system","volume":"61","author":"Santos","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.104.000299_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0166-4328(97)86039-1","article-title":"Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers","volume":"83","author":"Sarter","year":"1997","journal-title":"Behav Brain Res"},{"key":"10.1124\/mol.104.000299_bib43","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/archneur.1990.00530120062011","article-title":"Clinical and positive emission tomographic studies in the extrapyramidal syndrome of dementia of the Alzheimer type","volume":"47","author":"Tyrrell","year":"1990","journal-title":"Arch Neurol"},{"key":"10.1124\/mol.104.000299_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-0270(96)02213-3","article-title":"Effect of neostigmine on concentration and extraction fraction of acetylcholine using quantitative microdialysis","volume":"73","author":"Vinson","year":"1997","journal-title":"J Neurosci Methods"},{"key":"10.1124\/mol.104.000299_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","article-title":"Differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease using a dopaminergic presynaptic ligand","volume":"73","author":"Walker","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/mol.104.000299_bib46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s007020100008","article-title":"The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson\u2019s disease and dementia","volume":"108","author":"Werber","year":"2001","journal-title":"J Neural Transm"},{"key":"10.1124\/mol.104.000299_bib47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends Neurosci"},{"key":"10.1124\/mol.104.000299_bib48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1527-3458.2002.tb00237.x","article-title":"Nicotinic cholinergic modulation: galantamine as a prototype","volume":"8","author":"Woodruff-Pak","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1124\/mol.104.000299_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0301-0082(91)90006-M","article-title":"Cholinergic systems in mammalian brain and spinal cord","volume":"37","author":"Woolf","year":"1991","journal-title":"Prog Neurobiol"},{"key":"10.1124\/mol.104.000299_bib50","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nn769","article-title":"Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum","volume":"4","author":"Zhou","year":"2001","journal-title":"Nature Neurosci"},{"key":"10.1124\/mol.104.000299_bib51","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J Neurobiol"},{"key":"10.1124\/mol.104.000299_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1073858402239588","article-title":"Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems","volume":"9","author":"Zhou","year":"2003","journal-title":"Neuroscientist"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24056360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24056360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.104.000299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:47:24Z","timestamp":1740041244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24056360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0026895X24056360"],"URL":"https:\/\/doi.org\/10.1124\/mol.104.000299","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.104.000299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}